New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
13:05 EDTABTAbbott says over 2,000 patients to be included in phase 3 program for HCV
Abbott released details on its phase 3 hepatitis C registrational program following results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease in Boston. Topline intent-to-treat results from the 12-week, triple-DAA regimens with ribavirin presented at the AASLD meeting this week found that 97.5%, or 77 of 79, of treatment-na´ve GT1 patients and 93.3%, or 42 of 45, in GT1 null responder patients achieved SVR12. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals, with and without ribavirin, for the treatment of HCV in genotype 1 non-cirrhotic, treatment-na´ve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks. The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r, ABT-267 and ABT-333. Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials, the company said.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
April 21, 2015
15:28 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
April 15, 2015
07:41 EDTABTEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
09:06 EDTABTAbbott and Sekisui announce collaboration for coagulation testing
Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use